Therapeutic Proteins
Strategies to Modulate Their Plasma Half-lives
1. Auflage
Erschienen am 31. Januar 2012
XVIII, 354 Seiten
978-3-527-64478-0 (ISBN)
Beschreibung
For this ready reference, the internationally renowned authority in the field, Roland Kontermann, has assembled a team of outstanding contributors from industry and academia to convey the worldwide knowledge on modifying therapeutic proteins in order to optimize their pharmacological potential. The result is a comprehensive work covering all approaches and aspects of the topic in one handy volume, making this indispensable reading for companies and research institutions working on the development of biopharmaceuticals.
Weitere Details
Weitere Ausgaben
Andere Ausgaben
Buch
02/2012
1. Auflage
Wiley-Blackwell
145,00 €
Artikel ist vergriffen; siehe andere Ausgabe
Person
Roland Kontermann obtained his PhD in Molecular Biology from the University of Heidelberg. After working as a postdoc in the laboratory of Sir Gregory Winter at the MRC Centre for Protein Engineering, Cambridge, UK, he was a group leader at the Institute of Molecular Biology and Tumor Biology of the University of Marburg, and subsequently Head of Research at vectron therapeutics AG. Since 2004 he is Professor of Biomedical Engineering at the Institute of Cell Biology and Immunology of the University of Stuttgart. Current research focuses on the development of recombinant bispecific and bifunctional antibody molecules, including half-life extension strategies, and targeted nanoparticulate carrier systems for tumor therapy. He has over 60 scientific publications and co-editor (together with Stefan Dübel) of the Antibody Engineering Lab Manual.
Inhalt
GENERAL INFORMATION
Half-life modulating strategies - an introduction (Roland Kontermann)
Pharmacokinetics and half-life protein of therapeutics (Bernd Meibohm)
HALF-LIFE EXTENSION THROUGH CHEMICAL AND POSTTRANSLATIONAL MODIFICATIONS
Half-life extension through PEGylation (Simona Jevsevar and Menci Kunstelj)
Half-life extension of therapeutic proteins via genetic fusion to recombinant PEG mimetics
(Uli Binder and Arne Skerra)
Half-life extension through O-glyosylation (Fuad Fares)
Polysialic acid and polysialylation to modulate antibody pharmacokinetics (Antony Constantinou, Chen Chen and Mahendra P. Deonarain)
Half-life extension through HESylation (Thomas Hey, Helmut Knoller and Peter Vorstheim)
HALF-LIFE MODULATION INVOLVING RECYCLING BY THE NEONATAL FC RECEPTOR
The biology of FcRn (Jonghan Kim)
Half-life extension by fusion to the Fc region (Jalal A. Jazayeri and Graeme J Carroll)
Monomeric Fc fusion Technology: an approach to create long lasting clotting factors (Jennifer A. Dumont, Xiaomei Jei, Robert T. Peters, Alvin Luk, Glenn F. Pierce and Alan J. Bitonti)
The diverse roles of FcRn: implications for antibody engineering (Sally Ward and Raimund J. Ober)
Half-life extension by fusion to albumin (Hubert J. Metzner, Thomas Weimer and Stefan Schulte)
AlbudAb(TM) technology platform: versatile albumin binding domains for the development of therapeutics with tunable half-lives (Christopher Herring and Oliver Schon)
Half-life extension by binding to albumin through an albumin-binding domain (Fredrik Frejd)
Half-life extension by binding to albumin through small molecules (Sabrina Trüssel, Joerg Scheuermann and Dario Neri)
HALF-LIFE EXTENSION WITH PHARMACEUTICAL FORMULATIONS
Half-life extension with pharmaceutical formulations: liposomes (Astrid Hartung and Gerd Bendas)
Half-life extension with pharmaceutical formulations: nanoparticles (Katharina Landfester)
Half-life modulating strategies - an introduction (Roland Kontermann)
Pharmacokinetics and half-life protein of therapeutics (Bernd Meibohm)
HALF-LIFE EXTENSION THROUGH CHEMICAL AND POSTTRANSLATIONAL MODIFICATIONS
Half-life extension through PEGylation (Simona Jevsevar and Menci Kunstelj)
Half-life extension of therapeutic proteins via genetic fusion to recombinant PEG mimetics
(Uli Binder and Arne Skerra)
Half-life extension through O-glyosylation (Fuad Fares)
Polysialic acid and polysialylation to modulate antibody pharmacokinetics (Antony Constantinou, Chen Chen and Mahendra P. Deonarain)
Half-life extension through HESylation (Thomas Hey, Helmut Knoller and Peter Vorstheim)
HALF-LIFE MODULATION INVOLVING RECYCLING BY THE NEONATAL FC RECEPTOR
The biology of FcRn (Jonghan Kim)
Half-life extension by fusion to the Fc region (Jalal A. Jazayeri and Graeme J Carroll)
Monomeric Fc fusion Technology: an approach to create long lasting clotting factors (Jennifer A. Dumont, Xiaomei Jei, Robert T. Peters, Alvin Luk, Glenn F. Pierce and Alan J. Bitonti)
The diverse roles of FcRn: implications for antibody engineering (Sally Ward and Raimund J. Ober)
Half-life extension by fusion to albumin (Hubert J. Metzner, Thomas Weimer and Stefan Schulte)
AlbudAb(TM) technology platform: versatile albumin binding domains for the development of therapeutics with tunable half-lives (Christopher Herring and Oliver Schon)
Half-life extension by binding to albumin through an albumin-binding domain (Fredrik Frejd)
Half-life extension by binding to albumin through small molecules (Sabrina Trüssel, Joerg Scheuermann and Dario Neri)
HALF-LIFE EXTENSION WITH PHARMACEUTICAL FORMULATIONS
Half-life extension with pharmaceutical formulations: liposomes (Astrid Hartung and Gerd Bendas)
Half-life extension with pharmaceutical formulations: nanoparticles (Katharina Landfester)
